Can Drug Firm Blacklisting by Madhya Pradesh health authorities stand when the State skipped the second-sample retesting its own tender document promised, and then let the batches expire? Not in this case, the Supreme Court has held, quashing three-year blacklisting and two-year debarment orders against a medicine supplier.
New Delhi: Adverse drug test reports that a supplier was never allowed to challenge through retesting cannot be made the basis of its blacklisting, the Supreme Court has held, setting aside orders of the Madhya Pradesh authorities that barred a medicine manufacturer from government tenders [M/s JPEE Drugs v. State of Madhya Pradesh and Others].
Justice Vikram Nath, Justice Augustine George Masih and Justice Sandeep Mehta allowed the appeals on October 6, 2026. Justice Sandeep Mehta authored the judgment, which is marked reportable and cited as 2026 INSC 1143.
Why the reports could not carry the punishment
The Bench drew on its earlier ruling in Medipol, which recognised a valuable right to have an adverse Government Analyst report tested by a superior laboratory, and extended that principle to administrative and contractual action:
“Though the present proceedings arise from administrative and contractual action and not from a prosecution under the Act, the appellant-firm was subjected to serious civil consequences of blacklisting and debarment on the basis of the Government Analyst’s reports. The failure to follow the procedure expressly stipulated in Clause 6, followed by the non-compliance with the High Court’s direction for re-testing within the stipulated period, has deprived the appellant-firm of an effective opportunity to challenge the very reports forming the foundation of the impugned action.”
“In these circumstances, the respondents cannot be permitted to sustain the impugned punitive action on the strength of reports which the appellant-firm was denied an effective opportunity to controvert despite its entitlement under the Tender document. The procedural infirmity, coupled with the irretrievable deprivation of the opportunity for re-testing, renders the orders of blacklisting and debarment unsustainable in law.”
The tender and the four batches
The appellant is a licensed firm that manufactures and supplies medicines to government hospitals. It bid in a tender floated by the Department of Public Health and Family Welfare, through the M.P. Public Health Services Corporation Limited (MPPHSCL), Bhopal, for drug supply to government hospitals across Madhya Pradesh, and won contracts for Ascorbic Acid (Vitamin C) Tablets IP 500 mg and Ethambutol Hydrochloride Tablets IP 400 mg.
A show-cause notice followed on September 23, 2024, after test reports declared four of its batches “Not of Standard Quality”. By orders of September 30, 2024, the firm was debarred for two years from supplying the Ethambutol tablets and asked to deposit the batch value of Rs 3,47,375. It was separately blacklisted for three years from MPPHSCL tenders over three Vitamin C batches, with a direction to deposit Rs 6,77,219. Its reply and representation were rejected on October 1, 2024.
A High Court order that stopped short
The firm went to the Madhya Pradesh High Court, which decided its writ petition by a judgment of October 27, 2025 and its review petition by a common order of February 12, 2026. The High Court found that the blacklisting orders had been passed without following Clause 6 of Annexure IX to the tender document, which requires a second sample from the batch to be sent to another laboratory once a drug is declared not of standard quality.
Yet the orders were left standing. The High Court directed fresh samples to go to the Central Government Laboratory within 15 days and made the continuance of the blacklisting depend on the result. That retesting never happened, and by the time the appeals reached the Supreme Court, the shelf life of all four batches had run out.
In the appeals, the firm argued that blacklisting and debarment are punitive and carry serious civil consequences, and that both the tender procedure and the principles of natural justice had been ignored.
The directions
The competent authority’s orders of September 30, 2024 and October 1, 2024 stand quashed. The High Court’s judgment of October 27, 2025 and review order of February 12, 2026 were set aside to the extent they refused to quash the blacklisting orders and tied their continuance to retesting. The appeals were allowed, and pending applications were disposed of.
What the ruling signals
Blacklisting is often called the civil death of a contractor, and public procurement bodies tend to treat a failed lab report as the end of the matter. Here, the judgment makes clear that when a tender document itself promises a second test, that promise is a binding procedural safeguard, not a formality the State may skip before punishing a supplier.
It also carries the drug-testing principle from criminal prosecutions into contractual penalties: where the State’s delay lets a sample expire and forecloses retesting, the adverse report cannot be the sole basis for punitive action. A court that finds the procedure breached should quash the penalty outright, rather than keep it alive pending a test that time may make impossible.
Case Title: M/s JPEE Drugs v. State of Madhya Pradesh and Others [Civil Appeals arising out of SLP (C) Nos. 14499-14500 of 2026]; 2026 INSC 1143
Bench: Justice Vikram Nath, Justice Augustine George Masih and Justice Sandeep Mehta, Supreme Court of India
Date of Judgment: October 6, 2026
Impugned Orders: Madhya Pradesh High Court judgment dated October 27, 2025 and review order dated February 12, 2026